Neuropsychological functioning and viral load in stable antiretroviral therapy-experienced HIV-infected children

Pediatrics

Volumn 115, Issue 2, 2005, Pages 380-387

  Jeremy, Rita J ^a,k   Kim, Soyeon ^b   Nozyce, Molly ^c   Nachman, Sharon ^d   McIntosh, Kenneth ^e   Pelton, Stephen I ^f   Yogev, Ram ^g   Wiznia, Andrew ^h   Johnson, George M ⁱ   Krogstad, Paul ^j   Stanley, Kenneth ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c JACOBI MEDICAL CENTER   (United States)

^d STONY BROOK UNIVERSITY   (United States)

^e BOSTON CHILDREN S HOSPITAL   (United States)

^f BOSTON MEDICAL CENTER   (United States)

^g NORTHWESTERN UNIVERSITY   (United States)

^h ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

ⁱ MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

^k UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

Antiretroviral agents; Behavior; Child; Cognitive science; HIV; Neurologic examination; Neuropsychological tests; Protease inhibitors

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DIDANOSINE; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE INHIBITOR; RITONAVIR; STAVUDINE; ZIDOVUDINE; ANTIRETROVIRUS AGENT; VIRUS RNA;

ARTICLE; CHILD; CHILD BEHAVIOR; COGNITION; COMPARATIVE STUDY; CORRELATION ANALYSIS; FEMALE; HAND MOVEMENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE STATUS; LINGUISTICS; MAJOR CLINICAL STUDY; MALE; MOTOR PERFORMANCE; NEUROPSYCHOLOGICAL TEST; PRIORITY JOURNAL; RANDOMIZATION; SCORING SYSTEM; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME; VIRUS DETECTION; VIRUS LOAD; ADOLESCENT; BEHAVIOR DISORDER; BLOOD; CD4 LYMPHOCYTE COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG COMBINATION; DRUG EFFECT; GENETICS; HUMAN IMMUNODEFICIENCY VIRUS 1; INFANT; ISOLATION AND PURIFICATION; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRESCHOOL CHILD; PSYCHOLOGICAL ASPECT; RANDOMIZED CONTROLLED TRIAL; SHORT TERM MEMORY; VIROLOGY;

ADOLESCENT; ANTI-RETROVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; CHILD; CHILD BEHAVIOR; CHILD BEHAVIOR DISORDERS; CHILD, PRESCHOOL; COGNITION; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INFANT; MALE; MEMORY, SHORT-TERM; MOTOR SKILLS; NEUROPSYCHOLOGICAL TESTS; RNA, VIRAL; VIRAL LOAD; VOCABULARY;

EID: 20244377374     PISSN: 00314005     EISSN: 00314005     Source Type: Journal    
DOI: 10.1542/peds.2004-1108     Document Type: Article

References (54)

1. American Academy of Pediatrics, Task Force on Pediatric AIDS. Perinatal human immunodeficiency virus infection. Pediatrics. 1988;82:941-944
2. American Psychological Association, Task Force on Pediatric AIDS. Pediatric AIDS and human immunodeficiency virus infection: psychological issues. Am Psychol. 1989;44:258-264
3. Ammann AJ. Is there an acquired immune deficiency syndrome in infants and children? Pediatrics. 1983;72:430-432
4. Aylward EH, Butz AM, Hutton N, Joyner ML, Vogelhut JW. Cognitive and motor development in infants at risk for human immunodeficiency virus. Arch Pediatr Adolesc Med. 1992;146:218-222
5. Barnes DM. Brain function decline in children with AIDS. Science. 1986;232:1196
6. Belman AL. Acquired immunodeficiency syndrome and the child's central nervous system. Pediatr Clin North Am. 1992;39:691-714
7. Belman AL, Ultmann MH, Horoupian D, et al. Neurological complications in infants and children with acquired immune deficiency syndrome. Ann Neurol. 1985;18:560-566
8. Cooper ER, Hanson C, Diaz C, et al. Encephalopathy and progression of human immunodeficiency virus disease in a cohort of children with perinatally acquired human immunodeficiency virus infection. Women and Infants Transmission Study Group. J Pediatr. 1998;132:808-812
9. DeCarli C, Civitello LA, Brouwers P, Pizzo PA. The prevalence of computed tomographic abnormalities of the cerebrum in 100 consecutive children symptomatic with the human immune deficiency virus. Ann Neurol. 1993;34:198-205
10. Epstein LG, Sharer LR, Joshi VV, Fojas MM, Koeningsberger MR, Oleske JM. Progressive encephalopathy in children with acquired immune deficiency syndrome. Ann Neurol. 1985;17:488-496
11. Falloon J, Eddy J, Wiener L, Pizzo PA. Human immunodeficiency virus infection in children. J Pediatr. 1989;114:1-30
12. Gay CL, Armstrong FD, Cohen D, et al. The effects of HIV on cognitive and motor development in children born to HIV-seropositive women with no reported drug use: birth to 24 months. Pediatrics. 1995;96:1078-1082
13. Kauffman WM, Sivit CJ, Fitz CR, Rakusan TA, Herzog K, Chandra RS. CT and MR evaluation of intracranial involvement in pediatric HIV infection: a clinical-imaging correlation. Am J Neuroradiol. 1992;13:949-957
14. Kletter R, Jeremy RJ, Rumsey C, Weintrub P, Cowan M. Developmental decline in infants born to HIV-infected intravenous drug-using mothers. NIDA Res Monogr. 1989;95:409-410
15. Knight WG, Mellins CA, Levenson RL Jr, Arpadi SM, Kairam R. Brief report: effects of pediatric HIV infection on mental and psychomotor development. J Pediatr Psychol. 2000;25:583-587
16. Lobato MN, Caldwell MB, Ng P, Oxtoby MJ. Encephalopathy in children with perinatally acquired human immunodeficiency virus infection. Pediatric Spectrum of Disease Clinical Consortium. J Pediatr. 1995;126:710-715
17. Macmillan C, Magder LS, Brouwers P, et al. for the Women and Infants Transmission (WITS) Study. Head growth and neurodevelopment of infants born to HIV-1-infected drug-using women. Neurology. 2001;57:1402-1411
18. Nozyce M, Hittelman J, Muenz L, Durako SJ, Fischer ML, Willoughby A. Effect of perinatally acquired human immunodeficiency virus infection on neurodevelopment in children during the first two years of life. Pediatrics. 1994;94:883-891
19. Ultmann MH, Belman AL, Ruff HA, et al. Developmental abnormalities in infants and children with acquired immune deficiency syndrome (AIDS) and AIDS-related complex. Dev Med Child Neurol. 1985;27:563-571
20. Gartner S. Infection and dementia. Science. 2000;287:602-604
21. Centers for Disease Control and Prevention, Division of HIV/AIDS Prevention. Cases of HIV and AIDS in the United States, 2002. HIV/AIDS Surveill Rep. 2003;14:13,32
22. Barth RP, Pietrzak J, Ramler M. Families Living With Drugs and HIV: Intervention and Treatment Strategies. New York, NY: Guilford Press; 1993
23. Bornstein MH, Bradley RH, eds. Socioeconomic Status, Parenting, and Child Development. Mahwah, NJ: Erlbaum; 2003
24. Bradley RH, Corwyn RF. Socioeconomic status and child development. Annu Rev Psychol. 2002;53:371-399
25. Caldwell MB, Mascola L, Smith W, et al, and the Pediatric Spectrum of Disease Clinical Consortium. Biologic, foster, and adoptive parents: caregivers of children exposed perinatally to human immunodeficiency virus in the United States. Pediatrics. 1992;90:603-607
26. Evans GW. The environment of childhood poverty. Am Psychol. 2004;59:77-92
27. Hans SL. Studies of prenatal exposure to drugs: focusing on parental care of children. Neurotoxicol Teratol. 2002;24:329-337
28. Jeremy RJ, Bernstein VJ. Dyads at risk: methadone-maintained women and their four-month-old infants. Child Dev. 1984;55:1141-1154
29. Joslin, D, ed. Invisible Caregivers: Older Adults Raising Children in the Wake of HIV/AIDS. New York, NY: Columbia University Press; 2002
30. Sameroff AJ. Environmental risk factors in infancy. Pediatrics. 1998;102(suppl E):1287-1292
31. Sternberg R, Grigorenko EL, eds. Environmental Effects on Cognitive Abilities. Mahwah, NJ: Lawrence Erlbaum; 2001
32. Brouwers P, Moss H, Wolters P, et al. Effect of continuous-infusion zidovudine therapy on neuropsychologic functioning in children with symptomatic human immunodeficiency virus infection. J Pediatr. 1990;117:980-985
33. Pizzo PA, Eddy J, Falloon J, et al. Effect of continuous intravenous infusion of zidovudine (AZT) in children with symptomatic HIV infection. N Engl J Med. 1988;319:889-896
34. Nozyce M, Hoberman M, Arpadi S, et al. A 12-month study of the effects of oral zidovudine on neurodevelopmental functioning in a cohort of vertically HIV-infected inner-city children. AIDS. 1994;8:635-639
35. England JA, Baker CJ, Raskino C, et al. Zidovudine, didanosine, or both as the initial treatment for symptomatic HIV-infected children. N Engl J Med. 1997;336:1704-1712
36. Raskino C, Pearson DA, Baker CJ, et al. Neurologic, neurocognitive, and brain growth outcomes in human immunodeficiency virus-infected children receiving different nucleoside antiretroviral regimens. Pediatric AIDS Clinical Trials Group 152 Study Team. Pediatrics. 1999;104(3). Available at: www.pediatrics.org/cgi/content/full/104/3/e32
37. de Martino M, Tovo PA, Balducci M, et al. Reduction in mortality with availability of antiretroviral therapy for children with perinatal HIV-1 infection. Italian Register for HIV Infection in Children and the Italian National AIDS Registry. JAMA. 2000;284:190-197
38. Gortmaker SL, Hughes M, Cervia J, et al. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1. N Engl J Med. 2001;345:1522-1528
39. Nachman SA, Stanley K, Yogev R, et al. Nucleoside analogs plus ritonavir in stable antiretroviral therapy-experienced HIV-infected children: a randomized controlled trial. Pediatric AIDS Clinical Trials Group 338 Study Team. JAMA. 2000;283:492-498
40. Wiznia A, Stanley K, Krogstad P, et al. Combination nucleoside analog reverse transcriptase inhibitor(s) plus nevirapine, nelfinavir, or ritonavir in stable antiretroviral therapy-experienced HIV-infected children: week 24 results of a randomized controlled trial - PACTG 377. AIDS Res Hum Retroviruses. 2000;16:1113-1121
41. Krogstad P, Lee S, Johnson G, et al, and the Pediatric AIDS Clinical Trials Group 377 Study Team. Nucleoside-analogue reverse-transcriptase inhibitors plus nevirapine, nelfinavir, or ritonavir for pretreated children infected with human immunodeficiency virus type 1. Clin Infect Dis. 2002;34:991-1001
42. Yogev R, Lee S, Wiznia A, et al, for the Pediatric AIDS Clinical Trials Group 338 Study Team. Stavudine, nevirapine and ritonavir in stable antiretroviral therapy-experienced children with human immunodeficiency virus infection. Pediatr Infect Dis J. 2002;21:119-125
43. Bayley N. Bayley Scales of Infant Development. 2nd ed (Bayley II). San Antonio, TX: The Psychological Corporation; 1993
44. Wechsler D. Wechsler Preschool and Primary Scale of Intelligence-Revised (WPPSI-R). San Antonio, TX: The Psychological Corporation; 1989
45. Wechsler D. Wechsler Intelligence Scale for Children. 3rd ed (WISC-III). San Antonio, TX: The Psychological Corporation; 1991
46. Wechsler D. Wechsler Adult Intelligence Scale. 3rd ed (WAIS-III). San Antonio, TX: The Psychological Corporation; 1997
47. Lindsey JC, O'Donnell K, Brouwers P. Methodological issues in analyzing psychological test scores in pediatric clinical trials. J Dev Behav Pediatr. 2000;21:141-151
48. Thorndike RL, Hagen EP, Sattler JM. Stanford-Binet Intelligence Scale. 4th ed (S-B 4). Itasca, IL: Riverside Publishing; 1986
49. Wilson BC, Iacoviello JM, Wilson JJ, Risucci D. Purdue Pegboard performance of normal preschool children. J Clin Neuropsychol. 1982;4:19-26
50. Gardner RA, Broman M. The Purdue Pegboard: normative data on 1334 school children. J Clin Child Psychol. 1979;1:156-162
51. Conners CK. Conners' Parent Rating Scales. North Towanda, NY: Multi-Health Systems; 1990
52. Pearson DA, McGrath NM, Nozyce M, et al. Predicting HIV disease progression in children using measures of neuropsychological and neurological functioning. Pediatric AIDS clinical trials 152 study team. Pediatrics. 2000;106(6). Available at: www.pediatrics.org/cgi/content/full/106/6/e76
53. Llorente A, Brouwers P, Charurat M, et al. Women and Infant Transmission Study Group. Early neurodevelopmental markers predictive of mortality in infants infected with HIV-1. Dev Med Child Neurol. 2003;45:76-84
54. Culnane M, Fowler M, Lee S, et al. Lack of long-term effects of in utero exposure to zidovudine among uninfected children born to HIV-infected women. JAMA. 1999;281:151-157